The San Francisco Bay Area Adult Glioma Survival Study

本研究是旧金山弗朗西斯科湾区成人胶质瘤生存研究的延续，建立在16年的R 01基础上 资助的基于人群的研究和超过20年的P01和5年的SPORE资助的诊所- 在UCSF神经肿瘤学诊所（NOC）的基础研究;我们一起拥有全国最大的 具有多态性、血清学、肿瘤标志物 人口统计学和其他流行病学、治疗和生存数据。相关肿瘤的识别， 与胶质瘤生存相关的血清学、组成型多态性标记和患者特征可能 有助于为每个胶质瘤患者选择最佳治疗方法， 亚组的临床试验的基础上统一的预后快速治疗评估，并在提供更好的 为患者提供预后信息。在我们正在进行的和其他研究中确定的几个标志物， 进一步研究。这项研究的具体目标是：（1）继续（a）确定生命状况和相关的 1997-99年和2001-04年诊断的基于人群的成人发病神经胶质瘤病例的治疗信息， 通过UCSF NOC 2002-2006累积的患者（总数约1500）和（B）累积约720例患者 （问卷，血液，口腔和肿瘤标本）在UCSF NOC 2007-2011。（另一个人口 到2006年5月开始，将使2006-2011年诊断的患者总数达到约960例）。 (2)更深入地了解胶质母细胞瘤病例中生存率提高的机制， 在我们目前的系列中观察到IgE水平相对于正常或临界水平升高， 其他可能相关的血清标志物（sCD 23和sCD 14）、肿瘤标志物（CD 23蛋白和 IL 13 RA 2 m-RNA表达）和IL 4、IL 13、IL 4 R、IL 13 RA 1和IL 13 RA 2中的组成型SNP。这些 还将评估与肿瘤TP 53突变和表达以及EGFR扩增相关的标志物 和表达（在母研究中测量的标记物）。(3)确定MGMT或 肿瘤TP 53突变或表达影响存在或不存在肿瘤MGMT的生存 替莫唑胺治疗的患者中的甲基化。(4)从aims 2和 2007年7月1日至2011年6月30日在UCSF NOC就诊的新诊断患者中有3例，其中约100例GM 临床试验方案的病例。我们的研究小组与其他大脑孢子项目广泛合作 和脑肿瘤流行病学联盟，通过共享样本和数据以及联合赠款， 论文写作

This continuation of the San Francisco Bay Area Adult Glioma Survival Study builds on 16 years of R01 funded population-based research and more than 20 years of P01 and 5 years of SPORE funded clinic- based research in the UCSF Neuro-oncology Clinic (NOC); together we have among the country's largest datasets of well-characterized adult glioma patients with polymorphism, serologic, tumor marker, demographic and other epidemiologic, treatment, and survival data. The identification of relevant tumor, serologic, constitutive polymorphic markers and patient characteristics related to glioma survival is likely to aid in choosing the best treatments for each glioma patient, in enhancing definition of homogeneous subgroups for clinical trials based on uniform prognosis for rapid treatment evaluation, and in providing better prognostic information to patients. Several markers identified in our ongoing and other studies warrant further research. The study's specific aims are to: (1) Continue to (a) determine vital status and relevant treatment information for population based adult onset glioma cases diagnosed 1997-99 and 2001-04 and patients accrued through the UCSF NOC 2002-2006 (total number -1500) and (b) accrue -720patients (questionnaire, blood, buccal, and tumor specimens) in the UCSF NOC 2007-2011. (Another population based series to begin May 2006 will bring the total number of patients diagnosed from 2006-2011 to -960). (2) Obtain a greater understanding of the mechanisms of improved survival among glioblastoma cases with elevated versus normal or borderline IgE levels observed in our current series and validate and expand findings to other potentially related serum markers (sCD23 and sCD14), tumor markers (CD23 protein and IL13RA2 m-RNA expression), and constitutive SNPs in IL4, IL13, IL4R, IL13RA1, and IL13RA2. These markers will also be assessed in relation to tumor TP53 mutation and expression and EGFR amplification and expression (markers measured in the parent study). (3) Determine whether polymorphisms in MGMT or tumor TP53 mutation or expression influence survival in the presence of absence of tumor MGMT methylation in patients treated with temozolomide. (4) Validate promising markers obtained from aims 2 and 3 in newly diagnosed patients seen at the UCSF NOC from July 1, 2007-June 30, 2011 in -100of these GM cases on clinical trial protocols. Our study group collaborates extensively with other brain SPORE programs and the Brain Tumor Epidemiology Consortium through sharing of specimens and data and joint grant and paper writing.